Introducing HepConnect

Closing the gaps in care to combat the increasing rate of hepatitis C infections

Play button

Why HepConnect?

Together, we can
make a difference.

HepConnect is a five-year, multi-million-dollar initiative aimed at addressing the increase in hepatitis C (HCV) infections. In partnership with local organizations, we will develop and implement evidence-based solutions to meet the needs of people most affected by the opioid crisis.

To address growing HCV infection rates in greater Appalachia, HepConnect has three areas of focus:

Why hepatitis C?

A silent killer
within the
nation's
opioid crisis.

The United States is
experiencing rising rates
of hepatitis C (HCV),
fueled
by the nation's growing
opioid crisis. Many people
become
infected with HCV
by sharing contaminated
needles used to inject drugs.

2.4 million
people

are living with hepatitis C
(HCV) in the U.S.

50%

of those infected don't know they have the virus.1

Left Unchecked

HCV can lead to liver
damage, which can progress
to liver disease and liver cancer.
In 2015, nearly 20,000
people died of
complications
related to HCV.
2

Why Greater
Appalachia?

Going where the need
is greatest.

The largest increase in HCV infections occurs east of the Mississippi River, particularly in Appalachia and surrounding states.3 In central Appalachia, acute HCV infections rose 364% between 2006 and 2012.

In response to the intersecting opioid and HCV crises, Gilead is launching the HepConnect initiative, which will support community partnerships to combat the growing HCV infection rates in Indiana, Kentucky, North Carolina, Tennessee and West Virginia.

References:
1. https://www.cdc.gov/nchhstp/newsroom/2018/hepatitis-c-prevalence-estimates.html
2. https://www.cdc.gov/nchhstp/newsroom/2017/Hepatitis-Surveillance-Press-Release.html
3. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5846578/